ICCC logo

ImmuCell Corporation Stock Price

NasdaqCM:ICCC Community·US$61.5m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

ICCC Share Price Performance

US$6.80
3.23 (90.48%)
US$6.80
3.23 (90.48%)
Price US$6.80

ICCC Community Narratives

There are no narratives available yet.

Recent ICCC News & Updates

ImmuCell (NASDAQ:ICCC) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Aug 22
ImmuCell (NASDAQ:ICCC) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

We Think ImmuCell (NASDAQ:ICCC) Can Stay On Top Of Its Debt

May 22
We Think ImmuCell (NASDAQ:ICCC) Can Stay On Top Of Its Debt

ImmuCell Corporation Key Details

US$28.3m

Revenue

US$17.3m

Cost of Revenue

US$11.0m

Gross Profit

US$9.2m

Other Expenses

US$1.8m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 14, 2025
Earnings per share (EPS)
0.19
Gross Margin
38.88%
Net Profit Margin
6.23%
Debt/Equity Ratio
32.8%

ImmuCell Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Flawless balance sheet with acceptable track record.

2 Risks
2 Rewards

About ICCC

Founded
1982
Employees
73
CEO
Michael Brigham
WebsiteView website
immucell.com

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments: Scours and Mastitis. The company offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. It also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, the company developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: -2.8%
  • 3 Months: 5.3%
  • 1 Year: 13.4%
  • Year to Date: 11.7%
Over the last 7 days, the market has dropped 2.8%, driven by a pullback of 2.5% in the Information Technology sector. As for the longer term, the market has actually risen by 13% in the last year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›